Find News

Filter articles

Showing 1 to 10 of 2084 results

Tribal immunity not applicable in IPR, says Fed Circuit


Allergan and the Saint Regis Mohawk Tribe suffered a blow today as the US Court of Appeals for the Federal Circuit affirmed a decision rejecting use of tribal sovereign immunity in the inter partes review.

Teva counsel joins Greenberg Traurig


Greenberg Traurig announced on Monday, July 16, that it has added Brian Rubenstein as a shareholder in its Philadelphia office.

Novartis signs antibody licensing agreement with two biotechs

Belgium, Germany, Netherlands, Switzerland20-07-2018

Novartis has signed a global licensing agreement with two biotechnology companies centring on the development of an antibody treatment for inflammatory skin conditions.

Sanofi in $50m oncology collaboration

International, US19-07-2018

Sanofi has partnered with biotechnology company Revolution Medicines to develop treatments for multiple cancers.

Ropes & Gray hires life sciences partner from Fitzpatrick


Ropes & Gray has added Charlotte Jacobsen from Fitzpatrick, Cella, Harper & Scinto as a partner in the firm’s life sciences IP litigation practice.

Cantor Colburn adds new chair to life sciences group


US-based law firm Cantor Colburn has hired Bryan Zerhusen as a partner and chair of the firm’s life sciences practice group.

FDA’s Gottlieb launches biosimilars action plan


The US Food and Drug Administration is not going to play regulatory ‘whack-a-mole’ with companies trying to delay or derail the entry of biosimilar competitors, according to Scott Gottlieb, commissioner of the FDA.

AbbVie and Mylan agree Humira licensing deal


US-based biopharmaceutical company AbbVie entered into a patent licensing agreement with generics company Mylan yesterday.

Broad’s CRISPR patent hit with PGR petition


A CRISPR patent owned by the Broad Institute of Harvard and MIT is “unpatentable for indefiniteness”, according to an agriculture biotech company.

US court rejects Jazz attempt to revive Xyrem patents


The US Court of Appeals for the Federal Circuit has rejected Jazz Pharmaceuticals’ attempt to revive patents covering its narcolepsy drug Xyrem.

Showing 1 to 10 of 2084 results